Creyon Bio, a San Diego, CA and Research Triangle Park, NC-based drug development company, raised $40M in Seed and Series A funding.
The round was led by DCVC Bio and Lux Capital, with participation from Casdin Capital, Alexandria Venture Investments, and BioBrit.
The company intends to use the funds to continue the optimization of the platform, and expand the team.
Led by Co-founder, CEO and President Chris Hart, and Co-Founder and Chief Scientific Officer Swagatam Mukhopadhyay, Ph.D., Creyon Bio is a drug development company engineering RNA-based medicines and their components (oligonucleotide-based medicines or OBMs) with predictable safety and efficacy profiles. Creyon Bio creates proprietary, purpose-built datasets that inform machine learning models, rapidly identifying the design rules and engineering principles for safe and effective OBMs.
The Creyon Bio team also includes
- Nathan Billings, Ph.D., Chief Strategy Officer
- Monica McArthur, Ph.D., Chief Technology Officer
In addition to Hart and Mukhopadhyay, Creyon’s Board of Directors includes Kiersten Stead, Ph.D., DCVC Bio; Zavain Dar, Lux Capital; and Dennis Langer, M.D., J.D., an independent board member.
“With a team that includes chemists, biologists, and computational scientists, Creyon Bio’s cross-disciplinary approach breaks down silos to tackle the drug design problem from all angles and create an efficient path to patient impact,” said Zavain Dar, Lux Capital.